Adial Pharmaceuticals, Inc. announced that Bankole A. Johnson, M.D., DSc., M.B., ChB., M.Phil., DFAPA, FRCPsych, FACFEI has joined the company as its Chief Medical Officer. In connection with this new position, Dr. Johnson will step down from the Board of Directors of Adial and from his position as Chairman, and will also leave his position as the Chair of the Department of Psychiatry at the University of Maryland to devote greater focus to his new duties with the company. Dr. Johnson is a neuroscientist and pioneer in the development of medications for the treatment of alcohol abuse and is the inventor of all patents covering AD04. As Chief Medical Officer, Dr. Johnson joins the Adial senior management team as Adial prepares to commence a Phase 3 clinical trial of AD04 for people suffering from Alcohol Use Disorder.